REGENOVA ADVANCED MULTI-PEPTIDE REGENERATIVE SYSTEM

PRODUCT OVERVIEW

REGENOVA is a purposefully designed multi-peptide system developed based on the principle of Multi-Axis Regenerative Synergy. It is formulated to support the body’s natural regenerative processes, help maintain balanced inflammatory responses, and promote healthy tissue structure and endogenous repair capacity.

REGENOVA™ combines four key peptides, each contributing distinct biological roles that work together in a coordinated manner:

  • GHK-Cu (Copper Tripeptide-1) – Supports tissue remodeling and gene expression related to structural proteins
  • BPC-157 – Supports tissue integrity and endothelial environment
  • TB-500 (Thymosin Beta-4 fragment) – Supports cellular migration and tissue architecture
  • KPV – Supports balanced inflammatory signaling and immune modulation

This combination creates a closed-loop biological cycle in which signals are initiated, coordinated, and amplified in a physiologically harmonious sequence — rather than acting in isolation.

Unlike single-peptide formulas that target one pathway, REGENOVA is structured as an integrated platform where each component supports complementary aspects of the body’s natural regenerative rhythm. It is designed for sustained, quality-focused support rather than short-term effects, making it suitable for in-depth wellness protocols or long-term biological maintenance.

INGREDIENTS & THEIR BIOLOGICAL ROLES

  • GHK-Cu (Copper Tripeptide-1)

Foundational support for tissue remodeling and gene expression. GHK-Cu is one of the most studied peptides in this category and has been shown in research to:

  • Support collagen type I & III synthesis
  • Influence expression of thousands of genes associated with structural maintenance
  • Help enhance endogenous antioxidant systems
  • Support microcirculation and connective tissue quality

In REGENOVA™, GHK-Cu serves as the “biological architect,” helping guide deeper, physiology-aligned structural support.

  • BPC-157

Support for tissue integrity and endothelial environment. Preclinical research indicates BPC-157 may:

  • Interact with growth factor pathways
  • Support tendon, ligament, and soft tissue structural maintenance
  • Help modulate nitric oxide (NO) systems related to tissue perfusion
  • Contribute to mucosal environment balance in the digestive tract
  • It helps create a stable biological foundation so other components can function optimally.

TB-500 (Thymosin Beta-4 fragment)

Support for tissue architecture and cellular movement. Research shows TB-500 influences:

  • Actin Cytoskeleton Regulation
  • Cellular migration and differentiation processes
  • Angiogenesis mechanisms
  • Elasticity and flexibility of soft tissues

It acts as a biological accelerator, supporting efficient cellular dynamics within controlled regenerative pathways.

KPV

Support for inflammatory balance and immune modulation. KPV is a small peptide studied for its role in:

  • Inhibiting the NF-κB pathway (central to inflammatory signaling)
  • Helping reduce pro-inflammatory cytokine production
  • Supporting balanced responses in the gut and low-grade inflammatory environments
  • Promoting immune modulation without broad suppression

KPV helps ensure the regenerative process stays on track by supporting a balanced inflammatory baseline.

CORE SYNERGISTIC MECHANISM OF REGENOVA™

Principle: “Not simple addition — but biological coordination.”

When the four peptides are introduced together, the body may respond with integrated signaling: initiation → coordination → amplification of natural regenerative processes. This differs from using individual peptides separately, where signals can be fragmented.

REGENOVA™ follows a layered physiological model:

  • Activation & gene support (GHK-Cu)

Stabilization of internal environment (BPC-157 + KPV)

Structural reorganization & cellular dynamics (TB-500)

Sustained integration & balance (ongoing interplay)

This creates a harmonious cycle that may help limit suboptimal tissue formation and support higher-quality structural outcomes.

  • Phased Biological Response (Illustrative Sequence)

Phase 1 – Signal Initiation: GHK-Cu helps activate gene expression and structural protein pathways.

Phase 2 – Environmental Stabilization: BPC-157 and KPV work together to support a balanced internal milieu and moderated inflammatory signaling.

Phase 3 – Structural Reorganization: TB-500 supports cellular movement and tissue architecture.

Phase 4 – Integration & Maintenance: Continued coordination helps sustain balanced regenerative activity.

SCIENTIFIC BACKGROUND

The peptides in REGENOVA™ have been investigated in various preclinical, in vitro, and some human topical studies for their individual mechanisms:

  • GHK-Cu: Multiple human topical studies (12 weeks) have shown improvements in skin density, elasticity, and wrinkle appearance compared to placebo or other creams. In vitro data support collagen synthesis and antioxidant activity.
  • BPC-157: Extensive preclinical (rodent and other animal models) data demonstrate effects on tissue integrity, cellular migration, and perfusion-related pathways. Limited large-scale human clinical trials; not FDA-approved for clinical use.
  • TB-500: Preclinical and mechanistic studies show support for cellular migration, angiogenesis, and tissue flexibility. Primarily animal/in vitro data; limited human clinical evidence.
  • KPV: Mechanistic and in vitro studies indicate modulation of NF-κB and cytokine pathways. Some animal models explore gut-related inflammatory balance. Primarily preclinical data.

Why Simultaneous Use May Differ from Individual Administration

Individual peptides may produce fragmented signaling. The coordinated blend in REGENOVA™ is designed to support Physiological Signal Integration — allowing the body to interpret the inputs as part of a more complete, harmonious process.

KEY CLAIMED BENEFITS (STRUCTURE/FUNCTION SUPPORT)

  • Supports the body’s natural tissue regeneration processes
  • Helps maintain balanced inflammatory responses
  • Promotes healthy connective tissue and skin quality
  • Supports overall biological maintenance and wellness protocols

USAGE GUIDELINES & SAFETY CONSIDERATIONS

REGENOVA™ is intended for professional and research use. It is not a drug and does not replace standard medical treatments. Optimal results are associated with consistent dosing over sufficient time under professional supervision. Strict sterile preparation and administration protocols must be followed.

CONTRAINDICATIONS: Do not use it if:

  • Pregnant or breastfeeding (insufficient safety data)
  • Diagnosed with active or uncontrolled cancer (due to regenerative and angiogenesis-related mechanisms)
  • Taking strong immunosuppressants or having active severe autoimmune conditions
  • History of severe allergic reactions to peptides or biologics
  • Experiencing acute infection or uncontrolled inflammation
  • Always consult a qualified healthcare provider before use.

POTENTIAL SIDE EFFECTS

Common (usually mild and transient):

Local injection site reactions (redness, mild swelling, temporary discomfort) — typically resolve within 24–72 hours

Less common:

Mild fatigue or warmth in the first 1–2 days

Temporary increase in tissue sensitivity (may reflect normal structural adjustment)

Rare: Itching, rash, or unexplained discomfort — discontinue and seek medical attention if occurs.

Risk Reduction

Use stable dosing rather than high or stacked doses

Follow strict sterile technique

Undergo proper screening and professional oversight

REGULATORY STATUS

REGENOVA™ has not been evaluated or approved by the U.S. Food and Drug Administration (FDA). The individual peptides are primarily studied in preclinical or limited human settings and are not approved for the claims described. Many compounded peptides, including several in this formulation, fall under FDA Category 2 or face restrictions on compounding due to safety and data considerations.

This product is intended for research, educational, and professional wellness exploration only.

IMPORTANT LEGAL DISCLAIMER

REGENOVA™ is not intended to diagnose, treat, cure, or prevent any disease. All statements have not been evaluated by the FDA. The information provided is for educational and scientific reference purposes only. Individual results may vary significantly.

Always consult with a licensed healthcare professional before using any peptide product. JN Beauty Solutions® does not provide medical advice.

For more product information, please contact

JN Beauty Solutions®

Beauty From Science

 

#JNBeautySolutions #BeautySolutionsUSA #Regenova #MultiPeptideSystem #RegenerativeSupport #BiologicalSynergy